Insulet | PODD - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
Abbott USD 3.27B 138M 2026-03
Align Technology USD 465.34M 23.67M 2026-03
AtriCure USD 84.55M 6.21M 2026-03
Avanos Medical USD 77.7M 1.1M 2026-03
Baxter International USD 728M 33M 2026-03
Becton, Dickinson and Co. USD 1.21B 180M 2026-03
Boston Scientific USD 1.78B 53M 2026-03
Cardinal Health USD 1.51B 6M 2026-03
Cooper Companies USD 676.2M 303.1M 2026-03
Dexcom USD 349.7M 49.8M 2026-03
Edwards Lifesciences USD 522.2M 80.7M 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Globus Medical USD 297.77M 20.7M 2026-03
ICU Medical USD 155.81M 3.04M 2025-12
Inogen USD 43.77M 510K 2024-06
Insulet USD 317.2M 14.2M 2026-03
Integra LifeSciences USD 178.24M 21.79M 2026-03
J&J USD 6.03B 719M 2026-03
Masimo USD 143.4M 15.4M 2026-03
Medtronic 2.96B 9M 2025-12
Merit Medical Systems USD 110.47M 4.36M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Solventum Corp USD 783M 24M 2026-03
Stryker USD 2.15B 17M 2026-03
Tandem Diabetes Care USD 99.86M 5.34M 2025-12
Teleflex USD 226.01M 3.64M 2026-03
West Pharmaceutical Services USD 99.5M 7M 2026-03
Zimmer Biomet Holdings USD 849.9M 5.8M 2026-03